William Blair Has Positive Outlook for IONS Q1 Earnings
William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...
Arizona State Retirement System Has $1.44 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the ...
American Association of Individual Investors6d
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
pharmaphorum2d
Novartis closes on EU approval for SMA gene therapy Zolgensma
The quick uptake has come despite the established presence on the market of Biogen’s Spinraza (nusinersen), an antisense drug given by injection into the spine, which became the first treatment ...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Medscape2d
Sciatic Nerve Injury Following Intramuscular Injection: A Case Report and Review of the Literature
When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...
pharmaphorum5d
Novartis offers reimbursement options as EU backs costly SMA therapy
Biogen’s Spinraza (nusinersen) is another pricey option already on the market requiring injections every four months, and Roche plans a European filing of its potential rival risdiplam this year.